Cardiometabolic
Novo’s €1.165B Bet Targets the Burden of Weekly Injections
Novo has licensed Nanexa’s PharmaShell drug-delivery platform in a deal worth up to €1.165 billion, targeting monthly and potentially quarterly peptide injections for obesity, type 2 diabetes and other cardiometabolic diseases.
ENDO 2026 reveals the GLP-1 revolution’s real challenge: delivery
Cholesterol prevention is moving earlier. Is Europe ready to treat inherited risk before adulthood?
Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits
WHO is preparing to ration the obesity drug revolution before it becomes another access disaster
Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems
Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem
Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology
HEARTS 2.0: Latin America moves beyond hypertension and into cardio-kidney-metabolic care
EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Cardiometabolic
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases